Cepheid

France In-Vitro Diagnostics (IVD) Market Report 2021-2026: Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021

The "France In-Vitro Diagnostics (IVD) Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "France In-Vitro Diagnostics (IVD) Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.
  • France In-Vitro Diagnostics market is expected to reach US$ 2.1 Billion by the end of the year 2026.
  • Another important IVD market in France is that the country's private medical analysis laboratories merge into larger units.
  • Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific and Sysmex Corporation are prime companies in the France In-Vitro Diagnostics (IVD) Market.

BiologyWorks Awarded ISO 13485:2016 Certification for Development of its SARS-CoV-2 Fast Molecular Reusable Diagnostic Test

Retrieved on: 
Tuesday, July 6, 2021

BiologyWorks , a medical test developer with a mission to deliver fast and accurate molecular testing, today announced that it has earned (ISO) 13485:2016 certification for its quality management processes in medical device manufacturing.

Key Points: 
  • BiologyWorks , a medical test developer with a mission to deliver fast and accurate molecular testing, today announced that it has earned (ISO) 13485:2016 certification for its quality management processes in medical device manufacturing.
  • BiologyWorks is the developer of the BiologyWorks k(now) test, a fast molecular test for qualitative detection of pathogens and molecular biomarkers for SARS-CoV-2 and other viruses and infections.
  • Our focus remains on fast-tracking our molecular technology to deliver testing that is fast, private, affordable, and effective.
  • This certification adds to BiologyWorks existing CE IVD European Council Directive 98/79/EC certification for manufacturers of in vitro diagnostic medical devices in the European Union.

United States In Vitro Diagnostics Market Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021

The "United States In Vitro Diagnostics Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States In Vitro Diagnostics Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.
  • In the United States, the growing prevalence of chronic and infectious diseases has spurred the development of the in-vitro diagnostics (IVD) market.
  • Besides, the United States In-Vitro Diagnostic market is broad and has various types of diagnostics instruments to perform different techniques.
  • In the United States, the In-vitro diagnostics market is currently in the South of the country, followed by the West being second.

Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Retrieved on: 
Wednesday, June 2, 2021

To help implement this outreach program, the Company has signed an agreement with Dr.

Key Points: 
  • To help implement this outreach program, the Company has signed an agreement with Dr.
  • Vu Le to be the Medical Director for the Companys CLIA WAIVED Mobile Laboratory.
  • Global WholeHealth Partners Corp. (OTC: GWHP) provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood.
  • Mr. Charles Strongo, the CEO and Chairman of Global WholeHealth Partners Inc., said: Global understands the need to be ahead of the virus to conquer the virus.

2021 COVID-19 At-Home Testing Trends and Future Market Potential Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021

b'Speculative Projection of Home Testing for Test Categories FY 2021 (COVID-19, UTIs, STDs, HIV, Cholesterol and Other Categories)\nNumber of Canada Authorized COVID-19 Testing Devices (Rapid Point-Of-Care, Antigen Testing Devices, Nucleic Acid Testing Devices [PCR], and Serological Testing Devices)\nSelected CE Marked Rapid, POC COVID-19 Tests (Abbott Laboratories, Cellex, Coris Bioconcept, Cue Health, HiberGene Diagnostics, Laipac Technology, LumiraDX, Mast Group, Mologic, MP Biomedicals, PerkinElmer, Roche Diagnostics, SD Biosensors, and Siemens Healthineers)\nMajor Sample Types Used in Rapid Diagnostic Tests For COVID-19 (Nasopharyngeal Swab, Anterior Nasal Swab, Saliva, and Breath)\nSelected COVID-19 Authorized Sample Collection Kits (Amazon, BioReference Laboratories, GenMark/Roche Diagnostics, Gravity Diagnostics, Laboratory Corp. America [LabCorp], LetsGetChecked, Quest Diagnostics, RapidRona, Walgreens, Color, DxTerity Diagnostics, Fluidigm, hims & hers, OraSure Technologies, Phosphorus Diagnostics, Thermo Fisher Scientific, Vitagene, and MicroGenDx)\nSelected COVID-19 Self-Tests Using A Nasal Swab (Abbott Labs, Becton Dickinson & Co [BD], Cue Health, Ellume, Eurofins Clinical Enterprise, Fulgent Genetics, Iowa State University, Laipac Technology, Lucira Health, Quidel Corp., Siemens Healthineers)\nSelected Saliva-Based Self-Tests for COVID-19 (Clinical Reference Laboratory, Fluidigm, Hoth Therapeutics, Medusa 19, Nuclein, OraSure Technologies, Vault Health, and Vitagene)\nSelected COVID-19 Tests Using Alternate Samples (Breathonix, Canary Health Technologies, Gadjah Mada University, GreyScan, Next-Gen, Northumbria University, Ohio State University, Scentech Medical, and PerkinElmer)\nMajor Test Technologies Used in Rapid Diagnostic Tests for COVID-19 (PCR, EIA, LF EIA, CRISPR, Biosensor, LAMP)\nSelected Home and POC Molecular COVID-19 Tests (Abbott Labs, BioFire Diagnostics/biomerieux,Cepheid, Clinical Reference Laboratory, Cue Health, Fluidigm, Fulgent Genetics, GenMark/Roche Diagnostics, HiberGene Diagnostics, Lucira Health, Mesa Biotech, OralDNA Labs, Vault Health, and Vitagene)\nSelected CRISPR and Biosensor-Based Devices for COVID-19 Testing (Arizona State University, Bilkent University, Blink Science, GLC Medical, Hoth Therapeutics, Identify Sensors Biologics, Iowa State University, Pennsylvania State University, Broad Institute of MIT, CSIR-Institute of Genomics, Gladstone Institutes, Mammoth Biosciences, and Sherlock Biosciences)\nSelected FDA EUA and CE Marked COVID-19 Antigen Immunoassays (Abbott Labs, AccessBio, Becton Dickinson & Co [BD] Ellume, Laipac Technology, Mast Group, Medusa 19, Mologic, PerkinElmer, Quidel Corp., Roche Diagnostics, SD Biosensor, and Siemens Healthineers)\nSelected FDA EUA and CE Marked COVID-19 Antibody Immunoassays (Assure Tech, bioLytical Laboratories, bio Merieux, Cellex, Eurofins Technologies, Healgen Scientific, NovaBay Pharmaceuticals, NOWDiagnostics, PerkinElmer, Quest Diagnostics, SD Biosensor, Vatic, and Verify Diagnostics)\nSelected OTC and DTC COVID-19 Test Initiatives (Abbott Labs, Becton Dickinson & Co [BD], Clinical Reference Laboratory, Cue Health, Ellume, Laboratory Corp. America [LabCorp], Laipac Technology, Lucira Health, Quest Diagnostics, and Quidel Corp.)\nSelected Novel COVID-19 Test Initiatives (3M, Fitbit, Identify Sensors Biologics, Johns Hopkins University, NeuTigers, Northwestern University, and Pennsylvania State University)\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005635/en/\n'

Key Points: 
  • b'Speculative Projection of Home Testing for Test Categories FY 2021 (COVID-19, UTIs, STDs, HIV, Cholesterol and Other Categories)\nNumber of Canada Authorized COVID-19 Testing Devices (Rapid Point-Of-Care, Antigen Testing Devices, Nucleic Acid Testing Devices [PCR], and Serological Testing Devices)\nSelected CE Marked Rapid, POC COVID-19 Tests (Abbott Laboratories, Cellex, Coris Bioconcept, Cue Health, HiberGene Diagnostics, Laipac Technology, LumiraDX, Mast Group, Mologic, MP Biomedicals, PerkinElmer, Roche Diagnostics, SD Biosensors, and Siemens Healthineers)\nMajor Sample Types Used in Rapid Diagnostic Tests For COVID-19 (Nasopharyngeal Swab, Anterior Nasal Swab, Saliva, and Breath)\nSelected COVID-19 Authorized Sample Collection Kits (Amazon, BioReference Laboratories, GenMark/Roche Diagnostics, Gravity Diagnostics, Laboratory Corp. America [LabCorp], LetsGetChecked, Quest Diagnostics, RapidRona, Walgreens, Color, DxTerity Diagnostics, Fluidigm, hims & hers, OraSure Technologies, Phosphorus Diagnostics, Thermo Fisher Scientific, Vitagene, and MicroGenDx)\nSelected COVID-19 Self-Tests Using A Nasal Swab (Abbott Labs, Becton Dickinson & Co [BD], Cue Health, Ellume, Eurofins Clinical Enterprise, Fulgent Genetics, Iowa State University, Laipac Technology, Lucira Health, Quidel Corp., Siemens Healthineers)\nSelected Saliva-Based Self-Tests for COVID-19 (Clinical Reference Laboratory, Fluidigm, Hoth Therapeutics, Medusa 19, Nuclein, OraSure Technologies, Vault Health, and Vitagene)\nSelected COVID-19 Tests Using Alternate Samples (Breathonix, Canary Health Technologies, Gadjah Mada University, GreyScan, Next-Gen, Northumbria University, Ohio State University, Scentech Medical, and PerkinElmer)\nMajor Test Technologies Used in Rapid Diagnostic Tests for COVID-19 (PCR, EIA, LF EIA, CRISPR, Biosensor, LAMP)\nSelected Home and POC Molecular COVID-19 Tests (Abbott Labs, BioFire Diagnostics/biomerieux,Cepheid, Clinical Reference Laboratory, Cue Health, Fluidigm, Fulgent Genetics, GenMark/Roche Diagnostics, HiberGene Diagnostics, Lucira Health, Mesa Biotech, OralDNA Labs, Vault Health, and Vitagene)\nSelected CRISPR and Biosensor-Based Devices for COVID-19 Testing (Arizona State University, Bilkent University, Blink Science, GLC Medical, Hoth Therapeutics, Identify Sensors Biologics, Iowa State University, Pennsylvania State University, Broad Institute of MIT, CSIR-Institute of Genomics, Gladstone Institutes, Mammoth Biosciences, and Sherlock Biosciences)\nSelected FDA EUA and CE Marked COVID-19 Antigen Immunoassays (Abbott Labs, AccessBio, Becton Dickinson & Co [BD] Ellume, Laipac Technology, Mast Group, Medusa 19, Mologic, PerkinElmer, Quidel Corp., Roche Diagnostics, SD Biosensor, and Siemens Healthineers)\nSelected FDA EUA and CE Marked COVID-19 Antibody Immunoassays (Assure Tech, bioLytical Laboratories, bio Merieux, Cellex, Eurofins Technologies, Healgen Scientific, NovaBay Pharmaceuticals, NOWDiagnostics, PerkinElmer, Quest Diagnostics, SD Biosensor, Vatic, and Verify Diagnostics)\nSelected OTC and DTC COVID-19 Test Initiatives (Abbott Labs, Becton Dickinson & Co [BD], Clinical Reference Laboratory, Cue Health, Ellume, Laboratory Corp. America [LabCorp], Laipac Technology, Lucira Health, Quest Diagnostics, and Quidel Corp.)\nSelected Novel COVID-19 Test Initiatives (3M, Fitbit, Identify Sensors Biologics, Johns Hopkins University, NeuTigers, Northwestern University, and Pennsylvania State University)\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005635/en/\n'

GetMyDNA Receives FDA EUA for COVID-19 Test Home Collection Kit for Direct-to-Consumer Purchase

Retrieved on: 
Wednesday, March 10, 2021

This news means the COVID-19 Test Home Collection Test Kit DTC is available without a doctor's prescription and can be given directly to individuals who are not experiencing symptoms from COVID-19.

Key Points: 
  • This news means the COVID-19 Test Home Collection Test Kit DTC is available without a doctor's prescription and can be given directly to individuals who are not experiencing symptoms from COVID-19.
  • A PCR test is a highly reliable, high-complexity laboratory test.
  • GetMyDNA is powered by Gravity Diagnostics, a CLIA-certified, CAP-accredited laboratory that provides same-day results for 99% of samples received.
  • GetMyDNA provides affordable and reliable diagnostic home-testing solutions backed by telemedicine across the U.S. GetMyDNA is currently focused on providing gold-standard PCR COVID-19 testing and results through their FDA-authorized COVID-19 Test Home Collection Kit DTC.

Global Oncology Molecular Diagnostics Market Report 2020-2030: Major Players are Abbott Diagnostics, BD, Cepheid, Danaher, Beckman Coulter, Leica Biosystems, Gen Probe, Qiagen, Roche, Siemens

Retrieved on: 
Wednesday, February 17, 2021

Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.

Key Points: 
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.
  • Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market.
  • Global Oncology Molecular Diagnostics Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.

Global Oncology Molecular Diagnostics Market Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021

The "Oncology Molecular Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Molecular Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare.
  • The global oncology molecular diagnostics market is expected to decline from $5.58 billion in 2019 to $5.25 billion in 2020 at a compound annual growth rate (CAGR) of -5.81%.
  • The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market.

Global Industry for In Vitro Diagnostic Tests (2020 to 2025) - Impact Analysis of COVID-19

Retrieved on: 
Monday, December 21, 2020

This report provides reliable estimates and real-world forecasts for the In Vitro diagnostics industry for two decades.

Key Points: 
  • This report provides reliable estimates and real-world forecasts for the In Vitro diagnostics industry for two decades.
  • Now in its 13th edition, this report, 'The Worldwide Market for In Vitro Diagnostic (IVD) Tests' is the most essential report on the IVD industry.
  • The Worldwide Market for In Vitro Diagnostic Tests has been called "The Bible of the IVD Industry" by customers, which include top IVD firms.
  • The In Vitro diagnostics market is a global one, and The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 13th Edition reflects the international scope of the In Vitro diagnostics market size.

Cepheid Receives CE-IVD Registration for SARS-CoV-2, Flu A, Flu B and RSV Combination Test

Retrieved on: 
Tuesday, November 24, 2020

The four-in-one test is designed for use on any ofCepheid'salmost 30,000 GeneXpertSystems placed worldwide, with results delivered in approximately 36 minutes.

Key Points: 
  • The four-in-one test is designed for use on any ofCepheid'salmost 30,000 GeneXpertSystems placed worldwide, with results delivered in approximately 36 minutes.
  • "Things may get complicated this respiratory season as clinicians encounter a range of viral infections with symptoms overlapping with COVID-19, including Flu A, Flu B, and respiratory syncytial virus," said Dr.David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid.
  • Cepheid expects the first impact of the program in the fourth quarter of 2020 with additional capacity ramping through 2021.
  • Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.